Butamirate: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Indonesia prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Non-productive cough

Adult: As 50 mg tab: 2 or 3 tabs daily at intervals of 8 or 12 hours. As 7.5 mg/5 mL syr: 22.5 mg (15 mL) up to 4 times daily. Max: 90 mg (60 mL) daily. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
Child: Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).

Special Precautions

Hepatic and renal impairment. Pregnancy and lactation.

Adverse Reactions

Gastrointestinal disorders: Nausea, diarrhoea.
Immune system disorders: Hypersensitivity reaction.
Nervous system disorders: Drowsiness, dizziness.
Skin and subcutaneous tissue disorders: Rash, urticaria.

Patient Counseling Information

This drug may cause drowsiness or dizziness, if affected, do not drive or operate machinery.

Overdosage

Symptoms: Nausea, vomiting, diarrhoea, somnolence, dizziness, hypotension. Management: Supportive treatment.

Drug Interactions

Concomitant use with other cough medicines may cause an accumulation of bronchial secretions in the lungs.

Action

Description:
Mechanism of Action: Butamirate is an antitussive structurally unrelated to opioids. To suppress cough, it acts centrally by decreasing the tussigenic reflex. It also has peripheral anti-inflammatory and bronchospasmolytic activity.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed. Time to peak plasma concentration: 1.5 hours (syr).
Distribution: Plasma protein binding: Approx 95%.
Metabolism: Metabolised via hydrolysis into 2-phenyl butyric acid and diethylaminoethoxyethanol.
Excretion: Via urine (as metabolites). Elimination half-life: 6 hours.

Chemical Structure

Storage

Store below 30°C.

MIMS Class

Cough & Cold Preparations

ATC Classification

R05DB13 - butamirate ; Belongs to the class of other cough suppressants.

References

Anon. Butamirate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/06/2022.

Buckingham R (ed). Butamirate Citrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/06/2022.

Confomed 7.5 mg/5 mL Syrup, 50 mg Sustained Release Tablet (Lloyd Laboratories, Inc). MIMS Philippines. http://www.mims.com/philippines. Accessed 08/06/2022.

Sinecod Forte 7.5 mg/5 mL Syrup, 50 mg Sustained-release Tablet (Interphil Laboratories, Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 08/06/2022.

Disclaimer: This information is independently developed by MIMS based on Butamirate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com